8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) gene is one of the most frequently observed genetic alterations in acute myeloid leukemia (AML), with an incidence of about 20% to 30%. FLT3-ITD is significantly associated with a poor outcome, and offering an allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for patients harboring this mutation. Sorafenib is a tyrosine kinase inhibitor active against RAF, VEGF, and FLT3-ITD. It has been used in an off-label fashion in FLT3-ITD AML.

          Related collections

          Author and article information

          Journal
          Clin Lymphoma Myeloma Leuk
          Clinical lymphoma, myeloma & leukemia
          2152-2669
          2152-2669
          May 2015
          : 15
          : 5
          Affiliations
          [1 ] Department of Internal Medicine/Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
          [2 ] Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
          [3 ] Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon.
          [4 ] Department of Internal Medicine/Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon; Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon. Electronic address: bazarbac@aub.edu.lb.
          Article
          S2152-2650(14)00540-0
          10.1016/j.clml.2014.12.005
          25550214
          d2652819-472a-4601-a9d3-2558f8b6209d
          Copyright © 2015 Elsevier Inc. All rights reserved.
          History

          AML,FLT3-ITD,Maintenance,Sorafenib,Stem Cell Transplantation

          Comments

          Comment on this article